PDF(Pubmed)
Abstract：
OBJECTIVE: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and a global health problem. It is often diagnosed at advanced stage where hopeless for effective therapies. Identification of more reliable biomarkers for early detection of HCC is urgently needed. Cytokeratins are a marker of hepatic progenitor cells and act as a key player in tumor invasion. Herein, we sought to develop a novel score based on the combination of cytokeratin 18 (CK18) and cytokeratin 19 (CK19) with routine laboratory tests for accurate detection of HCC.
METHODS: Serum CK18, CK 19, α-fetoprotein, albumin and platelets count were assayed in HCC patients (75), liver cirrhosis patients (55) and healthy control (20). Areas under receiving operating curve (AUCs) were calculated and used for construction on novel score. A novel score named CK-HCC = CK 19 (ng/ml)×0.001+ CK18 (ng/ml)×0.004 + AFP (U/L)×5.4 - Platelets count (×109)/L×0.003 - Albumin (g/L)×0.27-36 was developed. CK-HCC score produces AUC of 0.919 for differentiating patients with HCC from those with liver cirrhosis with sensitivity and specificity of a cut-off 1.3 (i.e., less than 1.3 the case is considered cirrhotic, whereas above 1.3 it is considered HCC.
CONCLUSIONS: CK-HCC score could replace AFP during screening of HCV patients and early detection of HCC.
METHODS: Serum CK18, CK 19, α-fetoprotein, albumin and platelets count were assayed in HCC patients (75), liver cirrhosis patients (55) and healthy control (20). Areas under receiving operating curve (AUCs) were calculated and used for construction on novel score. A novel score named CK-HCC = CK 19 (ng/ml)×0.001+ CK18 (ng/ml)×0.004 + AFP (U/L)×5.4 - Platelets count (×109)/L×0.003 - Albumin (g/L)×0.27-36 was developed. CK-HCC score produces AUC of 0.919 for differentiating patients with HCC from those with liver cirrhosis with sensitivity and specificity of a cut-off 1.3 (i.e., less than 1.3 the case is considered cirrhotic, whereas above 1.3 it is considered HCC.
CONCLUSIONS: CK-HCC score could replace AFP during screening of HCV patients and early detection of HCC.
摘要：
目的：肝细胞癌（HCC）是肝脏的原发性恶性肿瘤，是全球健康问题。它通常在晚期阶段被诊断为有效疗法无望。迫切需要鉴定用于早期检测HCC的更可靠的生物标志物。细胞角蛋白是肝祖细胞的标志物，在肿瘤侵袭中起关键作用。在这里，我们试图根据细胞角蛋白18(CK18)和细胞角蛋白19(CK19)与常规实验室检测相结合,制定新的评分,以准确检测HCC.
方法：血清CK18、CK19、甲胎蛋白、在肝癌患者中检测白蛋白和血小板计数（75），肝硬化患者（55）和健康对照（20）。计算接收操作曲线下的面积(AUC)并用于构建新评分。新评分CK-HCC=CK19（ng/ml）×0.001CK18（ng/ml）×0.004AFP（U/L）×5.4-血小板计数（×109）/L×0.003-白蛋白（g/L）×0.27-36被开发。CK-HCC评分产生0.919的AUC，用于区分HCC患者与肝硬化患者的敏感性和特异性为1.3（即，小于1.3的病例被认为是肝硬化，而高于1.3则被认为是HCC。
结论：CK-HCC评分在HCV患者的筛查和HCC的早期发现中可以替代AFP。
方法：血清CK18、CK19、甲胎蛋白、在肝癌患者中检测白蛋白和血小板计数（75），肝硬化患者（55）和健康对照（20）。计算接收操作曲线下的面积(AUC)并用于构建新评分。新评分CK-HCC=CK19（ng/ml）×0.001CK18（ng/ml）×0.004AFP（U/L）×5.4-血小板计数（×109）/L×0.003-白蛋白（g/L）×0.27-36被开发。CK-HCC评分产生0.919的AUC，用于区分HCC患者与肝硬化患者的敏感性和特异性为1.3（即，小于1.3的病例被认为是肝硬化，而高于1.3则被认为是HCC。
结论：CK-HCC评分在HCV患者的筛查和HCC的早期发现中可以替代AFP。
